Product Search for novus: Novus Biologicals

NB400-104

SR-BI Antibody - BSA Free

(5 Reviews)

(227 Publications)

0.1 ml

NB400-104

Immunocytochemistry/Immunofluorescence: SR-BI Antibody [NB400-104] - SR-BI antibody was tested in human fibroblast samples fixed in 4% PFA and permeabilized in PBS (0.2% Tween). Primary incubation overnight at 4C using a 1:100 dilution in PBS (0.1% Tween) with 1% BSA. Secondary antibody is anti-rabbit conjugate to Alexa Fluor 488. SR-BI is shown in green and nucleus in blue (Hoescht 33342 stain).

Flow Cytometry: SR-BI Antibody [NB400-104] - An intracellular stain was performed on HeLa cells with SR-BI antibody NB400-104AF488 (blue) and a matched isotype control NBP2-24893AF488 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.

Western Blot: SR-BI Antibody [NB400-104] - Detection of SR-BI in rat H4IIE total cell lysates and plasma membrane proteins. Photo courtesy of product review by verified customer.

Immunohistochemistry: SR-BI Antibody [NB400-104] - Immunolocalization of SR-BI in adult mink testis using NB400-104. SR-BI labeling is visible at the surface and along the outline of the large vacuole. Photo courtesy of R.M. Pelletier, University of Montreal.

Immunohistochemistry-Paraffin: SR-BI Antibody [NB400-104] - FFPE tissue section of mouse liver using SR-BI antibody (Lot 8310) at 1:300 dilution with HRP-DAB detection and hematoxylin counterstaining. The antibody generated a specific membrane signal of SR-BI protein in the murine hepatocytes.

<b>Genetic Strategies Validation. </b>Knockdown Validated: SR-BI Antibody [NB400-104] - HCV replication was increased by CD36. Silence of CD36 decreased HCV infection and replication (n = 3). Huh7.5 cells were transfected with 0.2 u g CD36-HA plasmid or with 150 pmol siRNA for CD36 (B) for 48 hrs, and then were washed and infected with HCV (150 IU/cell) for 2 hrs, followed by washing and continuously incubating. Intracellular HCV RNA and proteins were detected in 96 hrs, and the cytotoxicity of siRNAs was measured in 96-wells plate with a MTT assay in B. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep21808) licensed under a CC-BY license.

Immunohistochemistry-Paraffin: SR-BI Antibody [NB400-104] - Staining of human adrenal cortex.

Immunocytochemistry/Immunofluorescence: SR-BI Antibody [NB400-104] - HeLa cells were fixed and permeabilized for 10 minutes using -20C MeOH. The cells were incubated with anti-SR-BI at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Immunohistochemistry-Paraffin: SR-BI Antibody [NB400-104] - FFPE tissue section of mouse liver using SR-BI antibody (Lot R-4) at 1:300 dilution with HRP-DAB detection and hematoxylin counterstaining. The antibody generated mainly a membranous signal of SR-BI protein in the murine hepatocytes.

Flow Cytometry: SR-BI Antibody [NB400-104] - Analysis of Huh7 and HepG2 cells using SR-B1 antibody NB400-104. Courtesy of Bruno Sainz, Jr., PhD, University of Illinois at Chicago.

Immunofluorescence assay on GIM biopsies of HCV-transplanted patients.Immunofluorescence assay on GIM polyp biopsies of HCV-transplanted patients, using antibodies against HCV receptors: CD81, SR-B1, Claudin-1, Occludin (Original magnification X400). (A, E) CD81 in colon (patient 26); (B, F) Claudin-1 in colon (patient 26); (C, G) Occludin in colon (C patient 28, G patient 26); (D) SR-B1 in antrum (patient 28); (H) SR-B1 in colon (patient 26). All the sections were clearly positive for the analyzed HCV receptors before (A-D) and after transplantation (E-H). Negative controls (I-N) were performed on GIM biopsies of HCV positive patients by omitting the primary antibodies, and by using polyclonal FITC-conjugated Donkey anti-mouse (I) and anti-rabbit (L, M, N) as secondary antibodies. (I CD81 in antrum; L Claudin-1 in polyp colon; M Occludin in antrum; N SR-B1 in polyp colon. Nuclei were counterstained with DAPI (blue). Scale bar 50 um. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0181683), licensed under a CC-BY licence.

HCV replication was increased by CD36. (B) Silence of CD36 decreased HCV infection and replication (n = 3). Huh7.5 cells were transfected with 0.2 ug CD36-HA plasmid (A) or with 150 pmol siRNA for CD36 (B) for 48 hrs, and then were washed and infected with HCV (150 IU/cell) for 2 hrs, followed by washing and continuously incubating. Intracellular HCV RNA and proteins were detected in 96 hrs, and the cytotoxicity of siRNAs was measured in 96-wells plate with a MTT assay in B. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep21808), licensed under a CC-BY licence.

ALDH2 rs671 modulates HDL-C levels in mice and human liver through increasing poly(ADP-ribosyl)ation of LXRalpha due to attenuated ALDH2/PARP1 interaction. (C) Western blotting analysis of ABCA1, ALDH2, LXRalpha, and SR-B1 expression in mouse liver tissue. WT, n = 3; rs671, n = 3. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35393951), licensed under a CC-BY licence.

ZA treatment increases ABCA1 and apoA-1 expression.(a) Western blot analysis of ABCA1, ABCG1 and SR-BI expression in untreated (ZA-) and ZA-treated (ZA+) THP-1 cells, U937 cells, CD14+ cells and corresponding DC subsets (DCTHP1, DCU937, DC). ABCA1 was already detectable in DCU937 and DC and its expression was upregulated by ZA. beta-tubulin was employed to check the equal protein loading per lane. The results are obtained from one representative experiment of three experiments. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/ncomms15663), licensed under a CC-BY licence.

Differentiation and characteristics of iHLCs. (d) Western blot analysis of protein expression in HCV-infected iHLCs compared to Huh7.5 cells of different host factors crucial for HCV infection. Tubulin served as loading control. Full-length blots are presented in Supplementary Figure 1. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29497123), licensed under a CC-BY licence.

Expression of cellular HCV receptors at the mRNA and protein levels.(a) mRNA copy numbers of CD81, occluding (OCLN), claudin-1 (CLDN1) and SR-BI were quantified in OASF, RASF and Huh-7.5 cells, normalized to the reference gene GAPDH. (b) Detection of CD81 on Huh-7.5 cells, OASF, and RASF by FACS analysis. (c-d) Detection of OCLN, CLDN1 and SR-BI in OASF and RASF by immunoblot analysis. Huh-7.5 cells were used as positive control and Hep-56.1D as negative control. In both the real-time PCR and the FACS analysis experiments the number of biological replicates was 3 and the number of experimental replicates was 2 (total n = 6). In immunoblotting detection, the number of biological replicates was 2 and the number of experimental replicates was 2 (n = 4). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26643193), licensed under a CC-BY licence.

miR-27a/b inhibit PINK1 accumulation upon mitochondrial damage. a, b Overexpression of miR-27a/b inhibited PINK1 accumulation upon mitochondrial damage. 48 h post-transfection, HeLa cells were treated with 10 μM CCCP or combination of 10 μM oligomycin and 4 μM antimycin as indicated for 2 h (n = 4, two-way ANOVA). c, d Inhibition of endogenous miR-27a/b increased PINK1 accumulation upon CCCP treatment. (n = 4, two-way ANOVA). PINK1 levels were normalized to corresponding GAPDH level and quantified as a percentage of control. Values are mean ± SEM (n.s. = non-significant, *p < 0.05, **p < 0.01, ***p < 0.001) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/27456084), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

A beta induces the expression of cell cycle regulatory proteins. (A) SK-N-MC cells were exposed to A beta (5 μM) for 24 h. The mRNA expression levels of CDK5, P35 and P39 were analyzed by real-time PCR. The mRNA expression level was normalized by beta -actin mRNA expression level. Data represent the mean ± SE. n = 4. (B)hif1 alpha specific- and non-targeting (NT) siRNA were transfected to the cells for 24 h prior to A beta treatment. Cyclin D1, CDK4, cyclin E, CDK2, HIF1 alpha and beta -actin was detected by western blot. n = 3. (C–F) Cells were pretreated with trehalose (10 μM), rapamycin (10 nM), PF4708671 (10 μM) and cycloheximide (4 μM) for 30 min prior to A beta treatment for 24 h. Cyclin D1, CDK4, cyclin E, CDK2 and beta -actin were detected by western blot. n = 3–6. (G) Mouse hippocampal neurons were transfected with hif1 alpha specific- and NT siRNAs for 24 h prior to A beta treatment for 24 h. Samples were blotted with Cyclin D1, CDK4, cyclin E, CDK2 and beta -actin specific antibodies. n = 3–6. (H) Mouse hippocampal neurons were pretreated with trehalose (10 μM) for 30 min and incubated with A beta for 24 h. cyclin D1, CDK4, cyclin E, CDK2, HIF1 alpha and beta -actin were analyzed by western blot. n = 3–6. Data are presented as a mean ± SE. *p < 0.05 vs. control, #p < 0.05 vs. A beta treatment. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28790888), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Yap deficiency suppresses cell proliferation in vivo and in vitro. (A-F) The Ki67 positive ratio of lens epithelial cells decreased in Yap-deficient mice at different stages (arrowheads indicate Ki67 positive cells). (G) The relative number of Ki67 positive lens epithelial cells (number of Ki67 positive lens epithelial cells / lens epithelium area). The data are shown as mean ± S.E.M. (Student’s t-test, *P<0.05, **P<0.01, n=10). (H-I) Knockdown efficiency of Yap in alpha TN4 cell using siRNA. (J-K) Cell viability and growth assay revealed that proliferation was downregulated in Yap knockdown alpha TN4 cells. The data are shown as mean ± S.E.M. (Two-way RM ANOVA, **P<0.01, n=5). Scale bars: 50 μm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/31011480), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Knockdown of CIP2A inhibited cell proliferation and DNA synthesis of HPV-16E7-expressing cells(A) Western blot analysis of protein level of 16E7 and CIP2A in RPE1-16E7 cells and (B) with CIP2A siRNA for 48 hr. (C) CCK8 assay of cell proliferation of RPE1-16E7 cells with CIP2A siRNA. (D) Flow cytometry of cells with CIP2A siRNA and labeled with BrdU for 2 hr, then stained with PI and BrdU; and (E), Quantification. Babe, vector control. **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/25650660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

ATO interferes with efficient HAdV replication center formation and reorganization of PML‐NBs. H1299 cells were infected with HAdV‐C5 wt at a multiplicity of 20 FFU per cell, treated with the depicted concentrations of ATO at 2 h p.i., fixed 48 h p.i. with 4% PFA and double labeled with mAb B6‐8 ( alpha ‐E2A) and pAb NB100‐59787 ( alpha ‐PML). Primary antibodies were detected using Alexa488 (PML, green) and Alexa647 (E2A, red) conjugated secondary antibodies. A) Number of PML‐NBs per cell in uninfected cells was determined using Volocity for at least n = 461 cells from two independent biological replicates. Statistically significant differences were determined using a one‐way ANOVA and Dunnet's T3 test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. B) The proportion of infected cells showing track‐like redistribution of PML‐NBs was determined by counting for at least n = 212 cells and normalization to untreated infected cells. C) The proportion of infected cells showing formation of HAdV replication centers marked by the viral protein E2A (lower plot) was determined by counting for at least n = 212 cells and normalization to untreated infected cells. D) Cells showing either viral replication centers with PML track‐like structures, replication centers without PML track‐like structures, no replication centers but PML track‐like structures or no replication centers, and no PML track‐like structures were counted for at least n = 214 (virus infected cells due to E2A signal detected: either untreated/0 µm or treated with ATO/1 or 2 µm) and represented in pie charts. Statistically significant differences were determined using a one‐way ANOVA and Dunnet's T3 test. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. E) H1299 cells were infected with HAdV‐C5 wt at a multiplicity of 20 FFU per cell, and treated with 0 or 2 µm of ATO at 2 h p.i. After 48 h, the cells were fixed with 4% PFA and stained using pAb NB100‐59787 ( alpha ‐PML) and mAb 6A‐11 ( alpha ‐E4orf3). Primary antibodies were detected using Alexa488 (PML, green) and Alexa647 (E4orf3, red) coupled secondary antibodies. Representative staining patterns for at least 30 uninfected cells treated with 0 or 2 µm ATO are shown in panels (a)–(d) and (m)–(p), infected cells treated with 0 or 2 µm ATO are shown in panels (e)–(l) and (q)–(x). Overlays of single fluorescence pictures (merge) are shown in panels (d), (h), (l), (p), (t), and (x). Data corresponds to two independent biological replicates performed and counted by different operators to avoid operator bias. Scale bar represents 10 µm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32328411), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$ABCC4 protein expression level in CRC cell lines. Western blot performed in standard reducing SDS PAGE conditions using goat anti ABCC4 (#PA5 18315, Thermo Scientific) and rabbit anti ABCG2 (#ORB 155559 Biorbyt). (A) Protein expression level of ABCC4 and ABCG2 in HT-29 stably overexpressing transcription factor Snail (HT29/Snail) and control HT-29. ABCC4 level in the membrane fraction (obtained by biotynylation using EZ-Link Sulfo -NHS-Biotin Thermo Scientific kit) of HT-29 control cells and HT-29 Snail n = 3. (B) ABCC4 protein expression level in CRC cells in different states of EMT: CCD841CoN (most epithelial), CaCo-2 (moderate EMT), and Colo-320 (most mesenchymal) n = 3. (C) ABCC4 protein abundance in Extracellular Vesicles (EVs) released from HT-29 control cells and two HT-29 stably overexpressing transcription factor Snail clones (HT-29/Snail and HT-29/Snail17), n = 2. (D) Intracellular cAMP level measurement. Accumulation of cAMP in HT29 cells was measured using a cAMP competitive kit (#581001 Cayman Chemical). Cells were incubated for 24 h with MK571 20 µM, or untreated ones were assayed according to the manufacturer’s protocol. Calculation were conducted using the Cayman data sheet. cAMP concentration of HT29 was set as 100%. T-test performed, n = 5; * p < 0.05; ** p < 0.005; *** p < 0.001. NS—not statistically significant. (E) PKA phosphorylation profile analysis. HT29 Snail cells were seeded on a 6-well plate. Then, 24 h after, full growth medium was changed into starving (FBS free) medium for 24 h. Next, 20uM of MK571 was added to cells for 60, 30, 5, and 1 min. Cells without the starving procedure were used as a positive control, and negative control cells were not treated with MK571. Phosphorylation profile analysis was performed using phospho-(ser/thr) PKA Substrate Antibody #9621 (Cell Signaling Technology). Significant time- (exposure) related impact on the phosphorylation profile was observed for 42 kDa and 95–100 kDa proteins in HT29 Snail cells compared to no time-related changes in control cells, n = 3. (F) HT-29/Snail PKA phosphorylation profile analyzed with densitometry; statistical significance estimated using T-test. * p < 0.05; ** p < 0.005; *** p < 0.001. NS—not statistically significant. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/33261018), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

Reactivity:

Hu, Mu, Rt, Po, ChHa, Ha, Md, Pm, Rb, SyHa

Species Glossary

Reactivity: Hu, Mu, Rt, Po, ChHa, Ha, Md, Pm, Rb, SyHa

Applications:

, , , , , , , , ,

Applications: , , , , , , , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB400-104AF350
Alexa Fluor 405	NB400-104AF405
Alexa Fluor 488	NB400-104AF488
Alexa Fluor 532	NB400-104AF532
Alexa Fluor 594	NB400-104AF594
Alexa Fluor 647	NB400-104AF647
Alexa Fluor 700	NB400-104AF700
Alexa Fluor 750	NB400-104AF750
Allophycocyanin	NB400-104APC
Biotin	NB400-104B
DyLight 350	NB400-104UV
DyLight 405	NB400-104V
DyLight 488	NB400-104G
DyLight 550	NB400-104R
DyLight 594	NB400-104DL594
DyLight 650	NB400-104C
DyLight 680	NB400-104FR
DyLight 755	NB400-104IR
FITC	NB400-104F
HRP	NB400-104H
Janelia Fluor 549	NB400-104JF549
Janelia Fluor 646	NB400-104JF646
PE	NB400-104PE
PerCP	NB400-104PCP
mFluor Violet 450 SE	NB400-104MFV450
mFluor Violet 500 SE	NB400-104MFV500
mFluor Violet 610 SE	NB400-104MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB400-104SS

compare

(select up to 3 products from this page to compare)

H00023435-M01

TDP-43/TARDBP Antibody (2E2-D3)

(3 Reviews)

(210 Publications)

0.1 mg

H00023435-M01

Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - PDI co-precipitates with TDP-43/TARDBP and is increased in mutant TDP-43 transgenic mouse spinal cords. Co-immunoprecipitation of wildtype and mutant Q331K TDP-43-mCherry from Neuro2a cell lysates using an anti-PDI antibody followed by TDP-43 immunoblot. Control immunoprecipitations were performed using untransfected (Untrans) or mCherry expressing cell lysates, buffer only with coprecipitating antibodies or TDP-43 Q331K cell lysates using an irrelevant, isotype-matched control antibody (IgG). Input control (2%) shows expression of mCherry-TDP43 in wildtype and Q331K cell lysates. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0081170) licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Analysis of monoclonal antibody to TARDBP on HeLa cell. Antibody concentration 10 ug/ml.

Immunohistochemistry-Paraffin: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - TARDBP on formalin-fixed paraffin-embedded human leiomyosarcoma. [antibody concentration 3 ug/ml]

Western Blot: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Analysis of TARDBP expression in transfected 293T cell line by TARDBP monoclonal antibody (M01), clone 2E2-D3.Lane 1: TARDBP transfected lysate(44.7 KDa).Lane 2: Non-transfected lysate.

Immunohistochemistry-Paraffin: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Analysis of monoclonal antibody to TARDBP on formalin-fixed paraffin-embedded human leiomyosarcoma tissue Antibody concentration 3 ug/ml.

<b>Genetic Strategies Validation. </b>Knockdown Validated: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Analysis of TARDBP over-expressed 293 cell line, cotransfected with TARDBP Validated Chimera RNAi ( Cat # H00023435-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with TARDBP monoclonal antibody (M01), clone 2E2-D3 (Cat # H00023435-M01 ). GAPDH ( 36.1 kDa ) used as specificity and loading control.

ELISA: TDP-43/TARDBP Antibody (2E2-D3) [H00023435-M01] - Detection limit for recombinant GST tagged TARDBP is 0.3 ng/ml as a capture antibody.

SINE compounds partially rescue motor deficits in an animal model of ALS/FTD. (b) Western blot demonstrating the expression of human TDP43 within the brains of AAV9-injected animals, which we have previously shown is largely restricted to neuronal cell types (Jackson et al.59). Full-length blots appear in Fig. S1. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-22858-w), licensed under a CC-BY licence.

CLIP shows that TDP-43 directly interacts with translational target mRNAs. (C and D) Plots showing percentage of input mRNA in the TDP-43 IP for the mRNAs indicated in three separate CLIP assays from MN1 cells. Performing CLIP from UV-treated cells leads to significant recovery and enrichment relative to Gapdh for all mRNAs examined (C). In the absence of UV treatment, much less mRNA is recovered and no significant enrichment relative to Gapdh mRNA is observed. Note that the Y-axis scale in D is 1000x smaller than in C, indicating strong crosslinking dependence of mRNA co-immunoprecipitation (n = 3, s.e.m. error bars, P-values indicated in the plot, unpaired two-tailed t-test). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30357366), licensed under a CC-BY licence.

PDI co-precipitates with TDP-43 and is increased in mutant TDP-43 transgenic mouse spinal cords.(A) Co-immunoprecipitation of wildtype and mutant Q331K TDP-43-mCherry from Neuro2a cell lysates using an anti-PDI antibody followed by TDP-43 immunoblot. Control immunoprecipitations were performed using untransfected (Untrans) or mCherry expressing cell lysates, buffer only with coprecipitating antibodies or TDP-43 Q331K cell lysates using an irrelevant, isotype-matched control antibody (IgG). Input control (2%) shows expression of mCherry-TDP43 in wildtype and Q331K cell lysates. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0081170), licensed under a CC-BY licence.

Reactivity:

Hu, Mu, Rt, Ba, I, Pm, Pp

Species Glossary

Reactivity: Hu, Mu, Rt, Ba, I, Pm, Pp

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Conjugate:

Unconjugated

Validated by:

Validated by:

compare

(select up to 3 products from this page to compare)

NB100-56566

TLR4 Antibody (76B357.1) - BSA Free

(5 Reviews)

(138 Publications)

0.1 mg

NB100-56566

Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Pericryptal Myofibroblasts are Responsible for Increased TLR4 Expression in a Subset of CRCs. Double-stained immunofluorescence for TLR4 (green) and vimentin (red) in normal (I), adenoma (II), and colon adenocarcinoma (III) (10x). In the stromal compartment of CRCs, immunofluorescent staining for TLR4 localized to the pericryptal myofibroblasts in a subset of samples. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.

Western Blot: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using 2 ug/mL on (A) human intestine and 6 ug/mL on (B) mouse intestine and (C) rat intestine lysate.

Flow (Intracellular): TLR4 Antibody (76B357.1) [NB100-56566] - Analysis using PE conjugate of NBP2-27149. An intracellular stain was performed on Jurkat cells with TLR4 antibody (76B357.1) NBP2-27149PE (blue) and an isotype control MAB004 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to phycoerythrin.

Immunocytochemistry/Immunofluorescence: TLR4 Antibody (76B357.1) [NB100-56566] - RH-30 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-TLR4 Antibody (76B357.1) NB100-56566 at 1 ug/ml overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.

Immunohistochemistry: TLR4 Antibody (76B357.1) [NB100-56566] - Immunofluorescent staining of TMAs. Representative tissue cores from normal (I), adenomatous polyps (II), and CRC (III and IV) are shown. Image collected and cropped by CiteAb from the following publication (//www.jeccr.com/content/33/1/45), licensed under a CC-BY license.

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of rat salivary gland tissue section at 1:100 dilution. The antibody generated a membrane-cytoplasmic staining in the tissue with stronger signal in ductal epithelial cells.

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Tissue section of normal human skin stained with antibody at 5 ug/mL. Membrane-cytoplasmic immunopositivity of TLR4 was primarily observed in the pigmented basel cells and the adjacent keratinocytes in the epidermal layer.

Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on RH30 cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Human skin stained with at 5 ug/mL, peroxidase-conjugate and DAB chromogen. Staining of formalin-fixed tissues is enhanced by boiling tissue sections in 10 mM sodium citrate buffer, pH 6.0 for 10-20 min followed by cooling at RT for 20 min.

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of TLR4 in FFPE human colon tissue using an isotype control (top) and NB100-56566 (bottom) at 5 ug/mL.

Immunohistochemistry-Paraffin: TLR4 Antibody (76B357.1) [NB100-56566] - Human testis tissue stained with antibody at 5 ug/mL.

Immunohistochemistry-Frozen: TLR4 Antibody (76B357.1) [NB100-56566] - This image is TLR4(green) and nucleus(blue) at area postrema of the adult male mouse brain, x20 magnification. Primary antibody diluted 1:500. IHC-Fr image submitted by a verified customer review.

Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - Analysis of formaldehyde fixed THP-1 cells (human monocytic leukemia cells) using 2 ug/10^6 cells TLR4 antibody (clone 76B357.1) with detection employing a donkey anti-mouse IgG (H+L) cross adsorbed secondary antibody, (DyLight 488 conjugated). Isotype control samples incubated with mouse IgG2b isotype control antibody were processed in parallal under the same assay conditions.

Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on Jurkat cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Flow Cytometry: TLR4 Antibody (76B357.1) [NB100-56566] - An intracellular stain was performed on Raw264.7 cells with TLR4 Antibody (76B357.1) NB100-56566 (blue) and a matched mouse IgG2b Kappa isotype control (orange) MAB004. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (35503, Thermo Fisher).

Representative images of immunohistochemical staining of pancreatic adenocarcinoma upregulated factor (PAUF) and toll-like receptor 4 (TLR4) in human ovarian cancer specimens. The top row (A,B) represents normal ovarian tissue, middle row (C,D) shows immunoreactivity of ovarian carcinomas and the bottom row (E,F) indicates immunonegativity of ovarian caricinoma. The stromal cells of normal ovarian tissue show immunonegativity for PAUF and TLR4. The scale bar represents 100 μm.

ALWPs significantly reduced LPS-induced cell-surface levels of TLR4. (C) BV2 microglial cells were pretreated with ALWPs (500 ug/ml) or PBS for 30 min, followed by treatment with LPS (1 ug/ml) or PBS for 5.5 h. Cell-surface biotinylation was then conducted with a TLR4 antibody recognizing the N-terminal region of TLR4. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30319390), licensed under a CC-BY licence.

Effect of Cucumis sativus L. extract (CSE) on LPS induced TLR4 expression. b) Representative Western Blot of TLR4 and relative housekeeping alpha-tubulin were reported. c Expression of TLR4 protein in pAECs treated with LPS (10 ug/ml) in the presence or absence of increasing doses CSE (0.02; 0.2; 2 mg/ml); data shown are representative of at least three independent experiments and represent the mean +/- SEM. Different letters above the bars indicate significant differences (p < 0.05 ANOVA post hoc Tukey's test) Image collected and cropped by CiteAb from the following publication (//bmccomplementalternmed.biomedcentral.com/articles/10.1186/s12906-018-2254-1), licensed under a CC-BY licence.

Dasatinib affects TLR4 signaling to regulate LPS-induced proinflammatory cytokine levels in BV2 microglial cells. d) BV2 microglial cells were treated with dasatinib (250 nM) or vehicle (1% DMSO) for 30 min followed by LPS (1 ug/ml) or PBS for 5.5 h, and cell surface biotinylation was conducted. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31655606), licensed under a CC-BY licence.

Corroboration of human AKR2–protein interactions with highest confidence. (A) Representation of the components of the protein pull-down experiment using c-Myc magnetic beads with Myc-tagged human AKR2. (B) Western blot analysis of AKR2–protein interactions. Interacting proteins were incubated with AKR2 and immunopresipitated with c-Myc magnetic beads specific for the AKR2 protein tag (I) or with the c-Myc magnetic beads only as negative control (C-). Recombinant interacting proteins were included as positive control (C+). Mouse or rabbit antibodies specific for each protein were used as primary antibodies and then anti-mouse or anti-rabbit secondary antibodies were used to identify the presence of the interacting proteins (red arrow). The origin of the primary antibody is shown. (C) Corroboration of human AKR2–AKR2 interaction using protein pull-down with c-Myc magnetic beads with human Myc-tagged AKR2. The experiment was conducted as described in (B). The origin of the primary antibody and predicted size for AKR2 monomer, dimer, and trimer together with bands corresponding to fragments of the mouse anti-c-Myc antibody attached to magnetic beads are shown. (D) In order to identify unrelated proteins eluted from the c-Myc magnetic beads, a similar experiment was conducted with selected proteins but incubating only with the secondary antibody. A lane of SDS-PAGE stained with Bio-Safe Coomassie Stain corresponding to c-Myc magnetic beads alone eluted using Laemmli sample buffer was included (C--). The bands corresponding to fragments of the mouse anti-c-Myc antibody attached to magnetic beads are shown. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32046307), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

$TDP1 depletion sensitizes glioblastoma-resistant cancer cells to temozolomide. (a) Cell lysates from RKO and DLD1 cancer cell lines were fractionated by SDS–PAGE and analyzed by immunoblotting using anti-TDP1 (Eurogentec), anti-Top1 (Santa Cruz), anti-Tubulin (Abcam) and anti-APE1 (Novus) antibodies (left). RKO and DLD1 cells were compared for their survival following exposure with the indicated doses of MMS for 15 min at 37°C (right). Data are the average of three independent experiments ± s.e.m. Where not visible, error bars are smaller than the symbol. (b) RKO cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by immunoblotting (left). Control RKO (RKOSc siRNA) and RKO cells in which TDP1 levels were depleted (RKOTDP1 siRNA) were examined for their survival following exposure to the indicated doses of MMS, as described earlier in the text (right). (c) Glioblastoma multiforme T98G and U87 cancer cell lines were analyzed for methylguanine methyltransferase (MGMT) expression using anti-MGMT antibodies (Abcam) (left). High-MGMT expressing T98G cells were compared with low-MGMT expressing U87 cells for their survival following exposure to increasing concentrations of the alkylating agent temozolomide (right). (d) TG98 cells were subjected to scrambled siRNA (Mock) or siRNA against TDP1 (TDP1KD) and cell lysates analyzed by immunoblotting (left). Control T98G cells (T98GSc siRNA) and cells in which TDP1 levels were depleted (TG98TDP1 siRNA) were incubated with DMSO or 150 μM of the APE1 inhibitor CRT0044876 ‘APEi’ for 2 h followed by additional incubation with the indicated concentrations of MMS for 15 min at 37°C. Cell survival was blindly scored from three independent biological repeats, and data are the average ± s.e.m. (right). (e) Model for the repair of temozolomide-induced DNA breaks. Temozolomide delivers a methyl group to purine bases of DNA, resulting in O6-methyl guanine, N7-methyl guanine and N3-methyl adenine. The primary cytotoxic lesion is believed to be O6-methyl guanine, which can be removed by a direct repair mechanism mediated by methylguanine methyltransferase (MGMT). Inherent and acquired resistance to temozolomide via MGMT expression presents a major challenge in cancer therapy, particularly for glioblastoma multiforme. TDP1 promotes the repair of methylated purines induced by temozolomide via a distinct non-canonical BER pathway. Increasing the load of unrepaired methylated purines by exploiting the limited availability of TDP1 alone or in combination with canonical BER factors such as APE1 provides a new synthetic lethal setting to improve the clinical outcome of temozolomide-based cancer therapy. Asterisks denote statistical differences (P < 0.05; t-test) between control and TDP1-deficient cells. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/24335147), licensed under a CC-BY license. Not internally tested by Novus Biologicals.$

OTULIN overexpression reduced the number of Iba-1+ microglial cells in the cortical ischemic penumbra in focal cerebral ischemia/reperfusion rats. A Representative images of Iba-1+ microglial cells that were morphologically classified into three types; scale bar = 10 μm. B Iba-1+ microglial cells in the ischemic penumbra and contralateral cortex of each group were detected by confocal immunofluorescence at 24 h, 72 h, and 7 days; scale bar = 75 μm. C The histogram represents the quantitative analysis of mean Iba-1 immunofluorescence intensity in each group (n = 6). Data are presented as the means ± SEMs; ###P < 0.001 versus the tMCAO group; &&&P < 0.001 versus the tMCAO+LV-Scramble group Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29544517), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

FKBP51 modulates EMT hallmarks. (a and b) FKBP51 silencing of SAN melanoma cells decreases TGF-beta and T beta RIII expression. Normalized expression rates (mean±S.D.) of TGF-beta (a, left) and T beta RIII (b, left) mRNA levels; (a, n=3; b, n=5). FKBP51 siRNA-treated sample expression=1. Western blot assay of TGF-beta in SAN melanoma cells treated with nonsilencing (NS) RNA or FKBP51 siRNA (a, right). Flow cytometric analysis of T beta RIII (endoglin) expression (b, right): FKBP51 siRNA-treated cells moved to the left relative to NS RNA-treated cells because of reduced staining (MFI: 111±10 and 64±3 in NS RNA and FKBP51 siRNA-treated cells, respectively). (c, and d) FKBP51 overexpression enhances TGF-beta and T beta RIII expression. Normalized expression of TGF-beta (c, left) and T beta RIII (d, left) mRNA in WT, EV-, or FKBP51-stably transfected melanoma cells. WT sample expression=1. (c, n=3; d, n=5). Western blot assay of TGF-beta levels in the same cells (c, right). Anti-Flag-labelled exogenous FKBP51. Flow cytometric analysis of T beta RIII expression (d, right). FKBP51-overexpressing cells moved to the right relative to WT or EV cells, indicating increased expression. (e) Graphic representation of cell counts ( × 10−3) in WT, EV-, or FKBP51-stably transfected melanoma cell cultures. Results are means of six independent experiments each performed in triplicate. (f) FKBP51 upregulates colony number and size. Colonies were counted under low magnification ( × 10) at four points on each dish. The data represent the means of two independent experiments performed in triplicate. Magnification: upper, × 10; lower × 40. (g) Boyden chamber filters invaded by melanoma cells. Filter was stained with Crystal Violet. OD value was obtained by reading the eluted Crystal Violet with a spectrophotometer at a wavelength of 570 nm. The increased OD in FKBP51 samples indicated that FKBP51-overexpressing cells invaded matrigel more efficiently than control cells. The data represent the means of three independent experiments performed in triplicate Image collected and cropped by CiteAb from the following open publication (//www.nature.com/articles/cddis2013109), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Functional assessment of Fanconi anemia pathway. (a) The experimental scheme for MMC treatment. Twenty‐four hours after plating, cells were cultured with or without MMC 1 μM for an additional 24 hr, after which the cells were harvested for western blot or immunostaining. (b) Western blot with FANCD2 antibody of BJ, proband fibroblasts, FANCB mutant (null) fibroblasts and FANCD2 mutant (null) fibroblasts. (c) Western blot with FANCD2 antibody of non‐FA control lymphoblasts (LCL), proband LCL‐A‐2017, proband LCL‐B‐2017, FANCB mutant (null) LCL, and FANCD2 mutant (null) LCL. (d) Representative figures of FANCD2 foci formation in the indicated cells. (e) Quantification of FANCD2 foci formation following treatment with or without 1 μM MMC. Experiments were performed in triplicate. One hundred cells were counted for each experiment Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/29193904), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Pot1a prevents DDR in HSCs. a, b Telomeric DDR in 8 week-old LSK cells upon Pot1a knockdown. a Immunocytochemical staining of TRF1 (green) and 53BP1 (red). Foci co-stained with TRF1 and 53BP1 were identified as TIFs. Nuclei were stained with TOTO3 (blue). Scale bar, 2 μm. b Frequency of TIFs per cell after 1 week of culture. Data are expressed as the mean ± SD (n = 100, *p < 0.01 by t-test). Representative data from three independent experiments are shown. c–f Telomeric DDR in donor-derived control-GFP or Pot1a overexpressing 8 week-old LSK cells 4 months post BMT. c Immunocytochemical staining of TRF1 (green) and 53BP1 (red). Nuclei were stained with TOTO3 (blue). Scale bar, 2 μm. d Frequency of TIFs per cell. Data are expressed as the mean ± SD (n = 120, *p < 0.01 by t-test). Representative data from 3 independent experiments are shown. e Immunocytochemical staining of TRF1 (green) and RPA32 (red). f Immunocytochemical staining of TRF1 (green) and pChk1 (red). Scale bar, 2 μm. g Flow cytometric analysis of Chk1 and pChk1 in donor-derived GFP+ LSKCD48–CD150+ cells after 5 months of 2nd BMT. Mean fluorescence intensity of Chk1 and pChk1 (left panels). Data are expressed as the mean ± SD (n = 3, *p < 0.01 by t-test). Representative FACS profiles of Chk1 and pChk1 in donor-derived GFP+ LSKCD48–CD150+ cells (right panels) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/28986560), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Lamin A/C-53BP1 interaction is regulated in a DNA damage-dependent manner. (A) Left; HDF were subjected to IR (10 Gy) and allowed to recover for 1 h. Association between A-type lamins and 53BP1 was assessed by immunoprecipitation of endogenous lamin A/C followed by immunoblotting with 53BP1 and lamin A/C antibodies. WCE, whole cell extract, IP: immunoprecipitates. WCE represents 5% input. Right; endogenous lamin A/C was immunoprecipitated and supernatants or pellets were analysed by immunoblotting for interaction with JMJD2A. (B) U2OS/GFP-lamin A cells were pretreated with caffeine (20 mm) for 1 h before exposure to IR (10 Gy, 1 h recovery). Cell extracts were then subjected to immunoprecipitation using GFP-Trap beads, and bound complexes were then analysed by immunoblotting using 53BP1 and GFP antibodies. WCE represents 1% input. (C) As in (C) except cells were pretreated with 10 μm ATMi for 1 h before IR. WCE represents 1% input. (D) U2OS/GFP-lamin A cells were subjected to laser micro-irradiation, fixed 1 h later and immunostained with gamma -H2AX antibody. Scale bar, 10 μm. (E) U2OS cells were transfected with siCTRL or siLMNA and subjected to laser micro-irradiation, fixed 15 min later and then processed for immunofluorescence with gamma -H2AX and 53BP1 antibodies. Scale bar, 10 μm. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/25645366), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Po, Bv, Ma, Pm, ChHa

Species Glossary

Reactivity: Hu, Mu, Rt, Po, Bv, Ma, Pm, ChHa

Applications:

, , , , , , , , , , , , , ,

Applications: , , , , , , , , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-5031A

Alt Catalog# IMG-5031A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-27149AF350
Alexa Fluor 405	NBP2-27149AF405
Alexa Fluor 488	NBP2-27149AF488
Alexa Fluor 532	NBP2-27149AF532
Alexa Fluor 594	NBP2-27149AF594
Alexa Fluor 647	NBP2-27149AF647
Alexa Fluor 700	NBP2-27149AF700
Alexa Fluor 750	NBP2-27149AF750
Allophycocyanin	NBP2-27149APC
Allophycocyanin/Cy7	NB100-56566APCCY7
Biotin	NBP2-27149B
DyLight 350	NBP2-27149UV
DyLight 405	NBP2-27149V
DyLight 488	NBP2-27149G
DyLight 550	NBP2-27149R
DyLight 594	NB100-56566DL594
DyLight 650	NBP2-27149C
DyLight 680	NBP2-27149FR
DyLight 755	NBP2-27149IR
FITC	NBP2-27149F
HRP	NBP2-27149H
Janelia Fluor 549	NB100-56566JF549
Janelia Fluor 646	NB100-56566JF646
PE	NBP2-27149PE
PE/Atto594	NB100-56566PEATT594
PE/Cy5.5	NB100-56566PECY55
PE/Cy7	NB100-56566PECY7
PerCP	NBP2-27149PCP
mFluor Violet 450 SE	NBP2-27149MFV450
mFluor Violet 500 SE	NBP2-27149MFV500
mFluor Violet 610 SE	NBP2-27149MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Azide Free	NBP2-27149
BSA Free	NB100-56566SS
Azide Free	NBP2-27149SS

compare

(select up to 3 products from this page to compare)

NB400-101

SR-BI Antibody - BSA Free

(1 Review)

(109 Publications)

0.1 ml

NB400-101

<b>Genetic Strategies Validation. </b>Knockout Validated: SR-BI Antibody [NB400-101] - Immunofluorescent analysis of SR-BI localization in liver of normal, Tie2-Scarb1 x Scarb1-KO, and Scarb1-KO mice. Liver sections from normal (b) and Tie2-Scarb1 x Scarb1-KO mice (c) were stained for SR-BI (red) and cytokeratin 8-18 (green).Merge image for normal mouse (b) demonstrates strong presence of SR-BI in hepatocytes (b, yellow signal) and absence of detectable level of SR-BI protein in liver of Tie2-Scarb1 x Scarb1-KO mice (c). In Scarb1-KO mice there was no detectable level of SR-BI protein (d, staining for SR-BI). Blue = DAPI. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/bmri/2015/607120/) licensed under a CC-BY license.

Western Blot: SR-BI Antibody [NB400-101] - Detection of SR-BI in mouse liver lysate (20 ug) using NB 400-101. ECL detection 5 seconds.

Flow (Intracellular): SR-BI Antibody [NB400-101] - An intracellular stain was performed on HeLa cells with NB400-101AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.

$<b>Genetic Strategies Validation. </b>Knockout Validated: SR-BI Antibody [NB400-101] - Western blot and Coomassie stain of membrane fractions isolated from livers of normal C57Bl/6N (lane 1), Scarb1-KO (lane 2), and LIV11-SCARB1 x Scarb1-KO (lane 3) mice. 20 ug of membrane protein was loaded into each lane. (a)Western blot (anti-SR-BI antibody). (b) Coomassie stain (loading control for Western blot) encompassing the same MW region as SR-BI. Aliquots from the same tube were loaded for the Western blot and for the Coomassie-stained gel, which shows comparable loading between the three samples. Image collected and cropped by CiteAb from the following publication (//www.hindawi.com/journals/bmri/2015/607120/) licensed under a CC-BY license.$

Western Blot: SR-BI Antibody [NB400-101] - Western blot analysis of ABCA1 and SR-B1 proteins from WT and Osbpl8KO mouse liver. The blots were probed with anti-beta-actin as a loading control. Densitometric quantification of the Western blot data is shown on the right. The results were normalized against beta-actin. The data represents mean +/- s.e.m. (n = 4). Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0058856), licensed under a CC-BY license.

Immunocytochemistry/Immunofluorescence: SR-BI Antibody [NB400-101] - HeLa cells were fixed and permeabilized for 10 minutes using -20C MeOH. The cells were incubated with anti-SR-BI at 2 ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse DyLight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

GDF11 inhibits TFEB activity. (a) AML‐12 cells were cultured for 48 h in presence of GDF11 (100 ng/ml). qRT‐PCR analysis of the mRNA levels of TFEB and its target genes VPS11 and ATP6V1H. (b) AML‐12 cells transient expressing GFP‐TFEB were cultured for 48 h in presence of GDF11 (100 ng/ml). Immunofluorescence confocal microscopy showing TFEB localization with or without GDF11 (original magnification, 400×). (c) Nuclear TFEB fluorescence intensity normalized to vehicle controls. (d) Western blot analysis of total TFEB protein expression. (e) Densitometry analysis of the total TFEB. (f) Western blot analysis of nuclear TFEB protein expression. (g) Densitometry analysis of the nuclear TFEB. The experiment was performed in triplicate with similar results. The data are shown as mean ± SD, *p 0.05. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/25582120), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt, Bv, ChHa, Md, Pm, Sj

Species Glossary

Reactivity: Hu, Mu, Rt, Bv, ChHa, Md, Pm, Sj

Applications:

, , , , , , , ,

Applications: , , , , , , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Validated by:

Validated by:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB400-101AF350
Alexa Fluor 405	NB400-101AF405
Alexa Fluor 488	NB400-101AF488
Alexa Fluor 532	NB400-101AF532
Alexa Fluor 594	NB400-101AF594
Alexa Fluor 647	NB400-101AF647
Alexa Fluor 700	NB400-101AF700
Alexa Fluor 750	NB400-101AF750
Allophycocyanin	NB400-101APC
Biotin	NB400-101B
DyLight 350	NB400-101UV
DyLight 405	NB400-101V
DyLight 488	NB400-101G
DyLight 550	NB400-101R
DyLight 594	NB400-101DL594
DyLight 650	NB400-101C
DyLight 680	NB400-101FR
DyLight 755	NB400-101IR
FITC	NB400-101F
HRP	NB400-101H
Janelia Fluor 549	NB400-101JF549
Janelia Fluor 646	NB400-101JF646
PE	NB400-101PE
PerCP	NB400-101PCP
mFluor Violet 450 SE	NB400-101MFV450
mFluor Violet 500 SE	NB400-101MFV500
mFluor Violet 610 SE	NB400-101MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NB400-101SS

compare

(select up to 3 products from this page to compare)

NBP2-24875

TLR3 Antibody (40C1285.6) - BSA Free

(87 Publications)

0.1 mg

NBP2-24875

Immunohistochemistry-Paraffin: TLR3 Antibody (40C1285.6) [NBP2-24875] - Mouse colon using TLR3 antibody (clone 40C1285.6) at 1:500 dilution with HRP-DAB detection and hematoxylin counterstaining. Intense signal was found in subset of cells at the bases of the crypts.

Flow Cytometry: TLR3 Antibody (40C1285.6) [NBP2-24875] - Expression of TLR3 in Fravel, L363, OPM1, RPMI8226, XG1, and NCI-H929 as determined by flow cytometry. HCMLs were stained using an intracellular staining protocol with TLR3 antibodies followed by relevant secondary fluorescent-conjugated antibodies. Filled histograms (purple) represent the isotype controls and the open histograms (red) indicate TLR3. Data are representative for analysis of >=2 independent experiments. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0060671) licensed under a CC-BY license.

Western Blot: TLR3 Antibody (40C1285.6) [NBP2-24875] - Analysis of TLR3 in lysates from A) human intestine and F) ovary using TLR3 antibody at 3 ug/ml. Goat anti-mouse HRP conjugate was used as secondary.

Western Blot: TLR3 Antibody (40C1285.6) [NBP2-24875] - HEK293T cells were transfected with TLR3, TLR3-9-3 and TLR3-3-9. Western blot was performed using anti-TLR3 or anti-HA antibodies. Anti-Beta-actin antibodies were used as a loading control. The representative data from three experiments are shown. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0092391) licensed under a CC-BY license.

Immunohistochemistry-Paraffin: TLR3 Antibody (40C1285.6) [NBP2-24875] - Tissue section of mouse intestine using TLR3 antibody (clone 40C1285.6) at 1:500 dilution with HRP-DAB detection and hematoxylin counterstaining. The representative image shows a punctate staining of the ER and endosomes in a subset of cells in Peyer's patches (organized lymphoid nodules) in the tested section.

Immunohistochemistry-Paraffin: TLR3 Antibody (40C1285.6) [NBP2-24875] - Analysis of TLR3 in (A) human gut lumen (longitudinal section, transverse region) using this antibody at 10 ug/ml (Data courtesy Dr. Elizabeth Furrie, University of Dundee) and mouse spleen tissue using isotype control (B) and this antibody (C) at 5 mg/ml.

NDRG2 inhibits cell proliferation and reduces the intracellular glucose levels of breast cancer cells. (A) T-47D, MCF-7, Bcap37, MDA-MB-231 and SK-BR-3 cells were collected for the extraction of proteins and analysed for N-myc downstream-regulated gene 2 (NDRG2) expression by immunoblotting. (B) SK-BR-3 cells with low NDRG2 expression were infected by an adenovirus carrying NDRG2 (Ad-NDRG2) or negative control LacZ (Ad-LacZ), and T-47D cells with high NDRG2 were transfected with small interfering RNA targeting NDRG2 (NDRG2 siRNA) or negative control siRNA (Con siRNA). Thereafter proteins were extracted from these cells and analysed by immunoblotting. beta -actin was used as a loading control. Before being cultured in 25 mM high-glucose (H.G.) or 5.5 mM low-glucose (L.G.) medium, SK-BR-3 cells were infected by Ad-NDRG2 (C) and T-47D cells were transfected by NDRG2 siRNA (D). Cell proliferation was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay for 1 to 5 days. (C) and (D) The data presented are means ± SD for three independent experiments; error bars represent SD from 8 replicative wells. (C) *P < 0.05 and **P < 0.01 versus H.G. Ad-LacZ. #P < 0.05 versus L.G. Ad-LacZ. (D) *P < 0.05 versus H.G. Con siRNA. (E) and (F) SK-BR-3 cells were cultured to glucose medium at concentrations of 0, 5, 25, 50 and 100 mM for 24 hours, and then the protein or mRNA was extracted for analysis by immunoblotting (E) or real-time PCR (F). beta -actin was used as a loading control. The data presented are means ± SD; error bars represented SD from 3 replicative wells. *P < 0.05 and **P < 0.01 versus control group. (G) SK-BR-3 or (H) T-47D cells, respectively, were infected with Ad-NDRG2 or transfected NDRG2 siRNA and cultured in a high-glucose medium (25 mM) for 48 hours. Next, cell glucose concentrations were measured. (G) and (H) The data presented are means ± SD of three independent experiments; error bars represent SD from 8 replicative wells. *P < 0.05 and **P < 0.01 versus control group. Image collected and cropped by CiteAb from the following open publication (//breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3628), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Characterization of selected mutant protein glycosylation status or localization.(A) Two independent, representative experiments to analyze the glycosylation status of GFP-NPC1 wild type and GFP-NPC1 P251C/L929C, as determined by immunoblot of indicated samples with anti-GFP antibodies after 6% SDS PAGE; samples were incubated at 70°C in SDS PAGE sample buffer for 10 min prior to loading. Molecular weight markers are shown at left in kilodaltons here and in all subsequent gels shown. (B), Localization of NPC1 P251/L929C/P249K/P259K in NPC1−/− HeLa cells as in Figure 1C. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32410728), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Notch-1 is identified as an intermediate molecule in the miR-1956-VEGF axis. (A) Notch-1 is a target gene for miR-1956. The sequence of miR-1956, the potential binding site at the 3' UTR of Notch-1 mRNA, and the nucleotides mutated in the Notch-1-3' UTR mutant are shown. HEK293 cells were transiently cotransfected with miR-1956 mimic or NC using luciferase reporter vectors. The luciferase activity was normalized to the activity of Renilla luciferase. Data are shown as mean ± SD from three independent experiments. *, significantly different from NC; **, p < 0.01. After transfection with 50 nmol/L of miR-1956 mimic for 3 days, the mRNA level of Notch-1 was determined using qRT-PCR (B), and the protein expression of Notch-1 was measured using western blotting (C). For B, data are shown as mean ± SD from three independent experiments. *, significantly different from control; **, p < 0.01. For C, representative images of two independent experiments are shown. Data are shown as mean ± SD. *, significantly different from control; **, p < 0.01. ADMSCs were transfected with 2.5 μg Notch-1 plasmid and 50 nmol/L miR-1956 mimic or 100 nmol/L miR-1956 inhibitor for 3 days, the intracellular expression of Notch-1 (D) and VEGF (E) was detected by western blotting. For D and E, representative images of four independent experiments are shown. Data are shown as mean ± SD. *, significantly different from the control group transfected with control plasmid and NC mimic or inhibitor; *, p < 0.01; **, p < 0.01. #, significantly different from the group transfected with Notch-1 plasmid and NC mimic or inhibitor; #, p < 0.05. One-way ANOVA followed by Tukey's post-test was performed (A-E). Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/31938051), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Ca

Species Glossary

Reactivity: Hu, Mu, Ca

Applications:

, , , , , ,

Applications: , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-315A

Alt Catalog# IMG-315A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-24875AF350
Alexa Fluor 405	NBP2-24875AF405
Alexa Fluor 488	NBP2-24875AF488
Alexa Fluor 532	NBP2-24875AF532
Alexa Fluor 594	NBP2-24875AF594
Alexa Fluor 647	NBP2-24875AF647
Alexa Fluor 700	NBP2-24875AF700
Alexa Fluor 750	NBP2-24875AF750
Allophycocyanin	NBP2-24875APC
Biotin	NBP2-24875B
Biotin	NBP2-24782
DyLight 350	NBP2-24875UV
DyLight 405	NBP2-24875V
DyLight 488	NBP2-24875G
DyLight 550	NBP2-24875R
DyLight 594	NBP2-24875DL594
DyLight 650	NBP2-24875C
DyLight 680	NBP2-24875FR
DyLight 755	NBP2-24875IR
FITC	NBP2-24875F
HRP	NBP2-24875H
Janelia Fluor 549	NBP2-24875JF549
Janelia Fluor 646	NBP2-24875JF646
PE	NBP2-24902
PE	NBP2-24875PE
PerCP	NBP2-24875PCP
mFluor Violet 450 SE	NBP2-24875MFV450
mFluor Violet 500 SE	NBP2-24875MFV500
mFluor Violet 610 SE	NBP2-24875MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NBP2-24875SS
Azide Free	NBP2-33263

compare

(select up to 3 products from this page to compare)

NBP2-24906

TLR7 Antibody - BSA Free

(4 Reviews)

(78 Publications)

0.1 mg

NBP2-24906

Immunocytochemistry/Immunofluorescence: TLR7 Antibody [NBP2-24906] - Immunolocalization of TLR7 (A) and glial fibrillary acidic protein (GFAP) (B) in murine myenteric plexus. Most of the GFAP positive cells were also positive for TLR7 in the merged image (C, yellow staining). (Courtesy of Barajon I, et al., Journal of Histochemistry and Cytochemistry, 57(11): 1013-;1023, 2009.)

Immunohistochemistry: TLR7 Antibody [NBP2-24906] - Expression of the TLRs 5 and 7 were evaluated in the PDAC tissue by their staining intensity using TLR5 antibody (NBP2-24787) and TLR7 antibody (NBP2-24906). Note negative staining in E and G; positive staining in F and H. For TLR7 immunopositivity was detectable in the cytoplasm with no notable membranous or nuclear positivity. TLR5 showed distinctive nuclear positivity, and detectable positivity in the cytoplasm in some samples. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0219245) licensed under a CC-BY license.

Immunohistochemistry-Frozen: TLR7 Antibody [NBP2-24906] - analysis of frozen mouse ear skin tissue using anti-TLR7 antibody. Image from verified customer review.

Immunohistochemistry-Frozen: TLR7 Antibody [NBP2-24906] - analysis of TLR7 in acetone-fixed, frozen mouse ear skin section using anti-TLR7 antibody. Image from verified customer review.

Western Blot: TLR7 Antibody [NBP2-24906] - Analysis using the Azide Free version of NBP2-24906. Detection of TLR7 in RAW cell lysate using this antibody.

Immunocytochemistry/Immunofluorescence: TLR7 Antibody [NBP2-24906] - Analysis using the Azide Free version of NBP2-24906. Staining of Raw 246.7 cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). Image objective 40x. An antibody dilution of 1:10 was used.

Immunohistochemistry-Paraffin: TLR7 Antibody - BSA Free [NBP2-24906] - Analysis of a FFPE tissue section of human skin using 1:200 dilution of TLR7 antibody (NBP2-24906). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.

Expression of TLR7 in lung tissues of non-smokers, smokers, and COPD patients. Total protein and mRNA were obtained from lung tissues of non-smokers (n = 15), smokers (n = 12), and COPD patients (n = 15). (E) Representative immunohistochemistry images are shown. The control IgG isotype showed negative staining. Data are presented as individual values and mean +/- standard deviation. Exact P values were obtained using Kruskal-Wallis and Dunn's post-hoc tests. Image collected and cropped by CiteAb from the following publication (//respiratory-research.biomedcentral.com/articles/10.1186/s12931-015-0179-5), licensed under a CC-BY licence.

Reactivity:

Hu, Mu, Rt

Species Glossary

Reactivity: Hu, Mu, Rt

Applications:

, , , , , , ,

Applications: , , , , , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Alt Catalog#

IMG-581A

Alt Catalog# IMG-581A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-24906AF350
Alexa Fluor 405	NBP2-24906AF405
Alexa Fluor 488	NBP2-24906AF488
Alexa Fluor 532	NBP2-24906AF532
Alexa Fluor 594	NBP2-24906AF594
Alexa Fluor 647	NBP2-24906AF647
Alexa Fluor 700	NBP2-24906AF700
Alexa Fluor 750	NBP2-24906AF750
Allophycocyanin	NBP2-24906APC
Biotin	NBP2-24906B
DyLight 350	NBP2-24906UV
DyLight 405	NBP2-24906V
DyLight 488	NBP2-24906G
DyLight 550	NBP2-24906R
DyLight 594	NBP2-24906DL594
DyLight 650	NBP2-24906C
DyLight 680	NBP2-24906FR
DyLight 755	NBP2-24906IR
FITC	NBP2-24777
HRP	NBP2-24906H
Janelia Fluor 549	NBP2-24906JF549
Janelia Fluor 646	NBP2-24906JF646
PE	NBP2-24906PE
PE	NBP2-31071
PerCP	NBP2-24906PCP
mFluor Violet 450 SE	NBP2-24906MFV450
mFluor Violet 500 SE	NBP2-24906MFV500
mFluor Violet 610 SE	NBP2-24906MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
Azide Free	NBP2-24905
Azide Free	NBP2-24905SS
BSA Free	NBP2-24906SS

compare

(select up to 3 products from this page to compare)

NB100-56723

TLR4 Antibody (HTA125) - BSA Free

(54 Publications)

0.1 mg

NB100-56723

Flow Cytometry: TLR4 Antibody (HTA125) [NB100-56723] - Analysis using Azide/BSA FREE version of NB100-56727. Cell surface analysis of TLR4 in stable HEK293/hTLR4 cells using this antibody. Secondary antibody goat anti-mouse IgG-PE at 0.25ug/10^6 cells. Both stable HEK293/hTLR4 and HEK293/Vector cell lines were equally stained.

Flow Cytometry: TLR4 Antibody (HTA125) [NB100-56723] - Staining of U937 cells with mouse anti human CD284:RPE. Image using the PE form of this antibody.

Flow Cytometry: TLR4 Antibody (HTA125) [NB100-56723] - Analysis using Azide/BSA FREE version of NB100-56727. Staining of human peripheral blood monocytes with Mouse anti Human CD284.

Block/Neutralize: TLR4 Antibody (HTA125) [NB100-56723] - Validation of the neutralizing effect of this antibody on TLR4 activity. The TLR4/MD-2/CD14/IL-8 Prom/LUCPorter HeLa cells were plated in 96-well white plates at 1 x 10^5 cells/well. After 16 h, cells were preincubated with different amounts of this antibody for 1 h and then stimulated with 10 ng/ml LPS for 6 h. Luciferase activity was then directly analyzed using the one-step luciferase reporter assay reagent. Data Summary: It inhibited LPS-mediated TLR4 activity in the TLR4/MD-2/CD14/IL-8 Prom/LUCPorter cell line. Image using the Azide Free format of this antibody.

Reactivity:

Hu, Mu, Ca

Species Glossary

Reactivity: Hu, Mu, Ca

Applications:

, , , , , , , ,

Applications: , , , , , , , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Alt Catalog#

IMG-417A

Alt Catalog# IMG-417A

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB100-56723AF350
Alexa Fluor 405	NB100-56727AF405
Alexa Fluor 405	NB100-56723AF405
Alexa Fluor 488	NBP2-24897
Alexa Fluor 532	NB100-56723AF532
Alexa Fluor 594	NB100-56723AF594
Alexa Fluor 647	NB100-56727AF647
Alexa Fluor 647	NB100-56723AF647
Alexa Fluor 700	NB100-56727AF700
Alexa Fluor 700	NB100-56723AF700
Alexa Fluor 750	NB100-56723AF750
Allophycocyanin	NB100-56723APC
Allophycocyanin	NB100-56727APC
Allophycocyanin/Cy7	NB100-56723APCCY7
Biotin	NBP2-24744
DyLight 350	NB100-56723UV
DyLight 350	NB100-56727UV
DyLight 405	NB100-56727V
DyLight 405	NB100-56723V
DyLight 488	NB100-56727G
DyLight 488	NB100-56723G
DyLight 550	NB100-56727R
DyLight 594	NB100-56723DL594
DyLight 650	NB100-56727C
DyLight 680	NB100-56727FR
DyLight 680	NB100-56723FR
DyLight 755	NB100-56723IR
DyLight 755	NB100-56727IR
FITC	NB100-56059
Janelia Fluor 549	NB100-56723JF549
Janelia Fluor 549	NB100-56727JF549
Janelia Fluor 646	NB100-56723JF646
Janelia Fluor 646	NB100-56727JF646
PE	NB100-56062
PE/Atto594	NB100-56723PEATT594
PE/Cy5.5	NB100-56723PECY55
PE/Cy7	NB100-56723PECY7
PerCP	NB100-56723PCP
PerCP	NB100-56727PCP

Available Formulations

Formulation	Catalog #	Availability	Price
Azide and BSA Free	NB100-56727
BSA Free	NB100-56723SS
Azide and BSA Free	NB100-56727SS

compare

(select up to 3 products from this page to compare)

NB400-113

SR-BI Antibody

(1 Review)

(45 Publications)

0.1 ml

NB400-113

Immunohistochemistry-Paraffin: SR-BI Antibody [NB400-113] - Analysis of a FFPE section of human adrenal gland tissue using 1:100 dilution of SR-BI antibody. The staining was developed using HRP-DAB based detection method and the nuclei of the cells were counterstained with hematoxylin. This antibody generated a specific staining of SR-BI/SCARB1 in the glandular cells. The staining was membrane-cytoplasmic in the zona glomerulosa cells while the signal was primarily localized to the membranes of the cells in the zona fasciculata and zona reticularis layers of the adrenal cortex.

Western Blot: SR-BI Antibody [NB400-113] - Cell surface expression of SR-BI in renal carcinoma cells. Western blot analysis of SR-BI in total cell lysates (left) and on the cell surface (right) in 786-O and 786-O-VHL cells. The Western blots were probed with anti-SR-BI (82 kDa), anti-TBP (40 kDa, used as a control for intracellular protein expression), and anti-Na+/K+-ATPase (110 kDa, used as a control for cell surface protein expression). Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30173145/) licensed under a CC-BY license.

SR-BI mediates cellular association of 125I-HDL and 125I-LDL in 786-O cells. A: Cell surface expression of SR-BI in renal carcinoma cells. Western blot analysis of SR-BI in total cell lysates (left) and on the cell surface (right) in 786-O and 786-O-VHL cells. The Western blots were probed with anti-SR-BI (82 kDa), anti-TBP (40 kDa, used as a control for intracellular protein expression), and anti-Na+/K+-ATPase (110 kDa, used as a control for cell surface protein expression). The 786-O and 786-O-VHL cells were pretreated with either anti-SR-BI neutralizing antibody or isotype (IgG) control for 1 h prior to assays, followed by incubation with 10 ug/ml of 125I-HDL (B) or 125I-LDL (C) for 1 h in the absence (total) or in the presence of 40-fold excess of unlabeled HDL or LDL (unspecific) at 37C. Specific association was calculated by subtracting unspecific values from total values. The results are represented as the mean +/- SEM of three independent experiments (each experiment performed in triplicate) with two batches of 125I-HDL and 125I-LDL. Significance was determined by Kruskal-Wallis test followed by Dunn's posttest. IgG control represents isotype control and anti-SR-BI Nab represents treatment with SR-BI neutralizing antibody. **P <= 0.01, +P <= 0.05. Complete blots are in supplemental Electrophoretic Blot SA. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30173145), licensed under a CC-BY licence.

Reactivity:

Hu, Mu, Rt

Species Glossary

Reactivity: Hu, Mu, Rt

Applications:

, , , , ,

Applications: , , , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

compare

(select up to 3 products from this page to compare)

NBP2-26244

TLR4 Inhibitor Peptide Set

(1 Review)

(47 Publications)

2 Vials

NBP2-26244

TLR4 Inhibitor Peptide Set [NBP2-26244] - TLR4/MD-2/CD14/NF-kB/SEAPorter stably transfected cells were plated in 96-well plates at 1x10^5 cells/well. After 16 h, cells were preincubated with various concentrations of inhibitor or control peptides (CP) for 1 h. Cells were then stimulated with 10 ng/ml LPS for 24 h. The secreted alkaline phosphatase (SEAP) was analyzed using the SEAPorter Assay Kit. Inhibitory effect on the LPS-mediated TLR4 activation by the VIPER peptide is shown in panel A, and IC50 of the VIPER peptide is described in panel B.

Reactivity:

Hu, Mu, Rt

Species Glossary

Reactivity: Hu, Mu, Rt

Applications:

, ,

Applications: , ,

Alt Catalog#

IMG-2011set

Alt Catalog# IMG-2011set

compare

(select up to 3 products from this page to compare)

NB100-56578

SARS Spike Protein Antibody

(1 Review)

(31 Publications)

0.1 mg

NB100-56578

Simple Western lane view shows recombinant SARS-CoV-2 Spike S2 Protein, loaded at 50 ng/mL. A specific band was detected for SARS-CoV-2 Spike S2 Protein at approximately 58 kDa (as indicated) using a serial dilution of Rabbit Anti-SARS-CoV Spike Protein Polyclonal Antibody (Catalog # NB100-56578) followed by incubation with HRP-conjugated Anti-Rabbit IgG Secondary Antibody. This experiment was conducted under reducing conditions and using the 12-230 kDa separation system.

SARS-CoV-2 spike overexpressed 293T cell lysate. Antibody dilution: 1:3000. Two bands for full length spike and cleaved S2 are shown, respectively. Western blot image submitted by a verified customer review.

Western blot shows SARS-CoV-1 Spike (Catalog # 10581-CV), SARS CoV-2 Spike (Catalog # 10586-CV), SArS-CoV-2 Spike S2 Subunit (Catalog # 10584-CV). Membrane was probed with 0.5 ug/mL of SARS Spike Protein Antibody (Catalog # NB100-56578) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for SARS-CoV-2 Spike S2 Subunit at approximately 70 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1. Internally validated Western blot.

Western blot analysis of SARS Spike Protein in (A) transfected and (B) untransfected mouse melanoma cell lysate.

Western blot shows recombinant protein SARS-CoV-2 Spike S2 Subunit. Membrane was probed with 0.5 ug/mL of Rabbit Anti-SARS Spike Protein Polyclonal Antibody (Catalog # NB100-56578) followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog # HAF008). A specific band was detected for SARS-CoV-2 Spike S2 Subunit at approximately 70 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1. Internally validated Western blot.

Simple Western lane view shows SARS-CoV-2 lysate, loaded at 1:20 dilution. SARS-CoV-2 Spike Protein was detected using 6.25 ug/mL of Rabbit Anti-SARS-CoV Spike Protein Polyclonal Antibody (Catalog # NB100-56578) followed by incubation with HRP-conjugated Anti-Rabbit IgG Secondary Antibody. This experiment was conducted under reducing conditions and using the 12-230 kDa separation system. SARS-CoV-2 lysate courtesy of University of Maryland.

Reactivity:

V, V

Species Glossary

Reactivity: V, V

Applications:

, , ,

Applications: , , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Alt Catalog#

IMG-557

Alt Catalog# IMG-557

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB100-56578AF350
Alexa Fluor 405	NB100-56578AF405
Alexa Fluor 488	NB100-56578AF488
Alexa Fluor 532	NB100-56578AF532
Alexa Fluor 594	NB100-56578AF594
Alexa Fluor 647	NB100-56578AF647
Alexa Fluor 700	NB100-56578AF700
Alexa Fluor 750	NB100-56578AF750
Allophycocyanin	NB100-56578APC
Biotin	NB100-56578B
DyLight 350	NB100-56578UV
DyLight 405	NB100-56578V
DyLight 488	NB100-56578G
DyLight 550	NB100-56578R
DyLight 594	NB100-56578DL594
DyLight 650	NB100-56578C
DyLight 680	NB100-56578FR
DyLight 755	NB100-56578IR
FITC	NB100-56578F
HRP	NB100-56578H
Janelia Fluor 549	NB100-56578JF549
Janelia Fluor 646	NB100-56578JF646
PE	NB100-56578PE
PerCP	NB100-56578PCP
mFluor Violet 450 SE	NB100-56578MFV450
mFluor Violet 500 SE	NB100-56578MFV500
mFluor Violet 610 SE	NB100-56578MFV610

compare

(select up to 3 products from this page to compare)

NB120-19294

LAMP-1/CD107a Antibody

(2 Reviews)

(33 Publications)

100 μg

NB120-19294

Immunocytochemistry/Immunofluorescence: LAMP-1/CD107a Antibody [NB120-19294] - Lamp1 (red) in HeLa cells.

Immunocytochemistry/Immunofluorescence: LAMP-1/CD107a Antibody [NB120-19294] - Cathepsin B (CathB) expression and localization in primary neurons. Colocalization of transfected CathB with LAMP-1/CD107a. CathB transfected neurons were examined by co-immunostaining of LAMP-1/CD107a and CathB. Yellow colored cytoplasmic spots are indicative of co-localization of transfected cathepsins and LAMP-1/CD107a. Scale bar = 10 micron. Image collected and cropped by CiteAb from the following publication (//molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-6-37), licensed under a CC-BY license.

EsxG-EsxH alters phagosomal GAL3, ubiquitin, and LAMP1. (A, C, and E) IF images of GAL3 (A), ubiquitin (FK2 antibody) (C), and LAMP1 (E) in BMDMs that were infected with DsRed-expressing H37Rv (WT) or the deltaesxH mutant for 3 h. Images are maximum-intensity projections. Scale bar, 10 um. Boxed areas in the merged image are shown in higher magnification in the rightmost panel. Mtb, M. tuberculosis. (B, D, and F) Automated image analysis was used to quantify the MFI of GAL3 (B), ubiquitin (D), and LAMP1 (F) colocalized with individual bacilli from 5 fields of a 12-mm coverslip. Data are means +/- SEM from one representative experiment from three (A, B, E, and F) or two (C and D) independent experiments. ****, P <= 0.0001, Student's t test. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30482832), licensed under a CC-BY licence.

Inhibition of H4K12ac with NU9056 modulates cytokine and chemokine production. After 5–7 days of differentiation, MDDCs were treated with NU9056 50 nM, 0.2% EtOH or both for 5 days. Supernatants collected were analyzed for 48 inflammatory cytokines and chemokines. Data is from 3 blots for untreated control, 2 blots each for treatment with 0.2% EtOH alone, treatment with NU9056 alone, and treatment with 0.2% EtOH plus NU9056. Cytokines chosen to be presented in the graph were selected on the basis of fold change (2 folds or more) compared to control. Each cytokine is detected in duplicates within each blot. Statistical differences were calculated using student’s t-test when individually compared to untreated control and indicated with a * (compared to control) and # (between treatments) for significant p value. Two-way ANOVA was carried out (p = 0.027). Panel a shows optical density values for cytokines IL-15, RANTES, TGF-beta 1 and TNF-alpha . Panel b shows optical density values for MCP2. In panel c, MCP-2 ELISA was carried out from cell culture medium at least three times in duplicates. Values detected in pg/mL are as follows, untreated control (322.4 ± 25.04), NU9056 50 nM (317.5 ± 14.3), 0.2% EtOH (401.7 ± 28.2) and 0.2% EtOH + NU9056 50 nM (321.6 ± 13.5, p = 0.03). Panels d–g show intracellular staining to measure MCP-2 levels in untreated or treated MDDCs. Data represented is from at least 3 experiments. Panel d shows % gated MCP-2 positive cells for untreated control (52.3% ± 2.3), NU9056 50 nM (45.8% ± 1.07), 0.2% EtOH (85.8% ± 5.2, p = 0.002) and 0.2% EtOH + NU9056 50 nM (29.6% ± 1.18, p = 0.0001). Panel e shows MFI values for MCP-2-FITC for untreated control (2510 ± 29), NU9056 50 nM (2151 ± 43), 0.2% EtOH (4260 ± 603, p = 0.04) and 0.2% EtOH + NU9056 50 nM (1459 ± 297, p = 0.01). Panel f shows an overlay histogram of MCP-2-FITC for all the samples as shown in legend. Panel g shows representative single cell images. Image collected and cropped by CiteAb from the following open publication (//www.nature.com/articles/s41598-017-11172-6), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

DDR and NF-kappa B are activated concomitantly in senescent MEFs and aged tissues. (A) Immunoblot detection of p-p65 and total p65 in liver tissue from 16-week-old WT (n=3) and Ercc1-/ delta (n=3) mice. (B) Immunoblot detection of phosphorylation of ATM and downstream targets gamma H2AX and p21 in liver from 16-week-old WT and Ercc1-/ delta mice. (C) Immunoblot detection of phosphorylation of NF-kappa B and I kappa B alpha in liver lysates from 3, 12 and 24 month-old WT mice. n=3 mice per group. (D) Immunoblot detection of p-ATM, ATM and p21 in the same liver lysates. (E) Immunoblot detection of DDR effectors in nuclear extracts from passage 5 WT and Ercc1-/- MEFs, grown at 20% oxygen. (F) Level of NF-kappa B activation is higher in Ercc1-/- MEFs compared to WT MEFs at passage 5, as measured by Immunoblot detection of p-p65 and total p65 in WT and Ercc1-/- MEFs at passage 5 after culturing in 20% oxygen. (G) Representative images of immunofluorescent detection of p65 and NEMO in passage 4 WT and Ercc1-/- MEFs grown at 20% oxygen. Blue: DAPI staining; Green: p65 (top panel) or NEMO (bottom panel). Images were taken at the magnification of 60x. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32201398), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Reactivity:

Hu, Mu, Rt

Species Glossary

Reactivity: Hu, Mu, Rt

Applications:

, ,

Applications: , ,

Host:

Rabbit Polyclonal

Host: Rabbit Polyclonal

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NB120-19294AF350
Alexa Fluor 405	NB120-19294AF405
Alexa Fluor 488	NB120-19294AF488
Alexa Fluor 532	NB120-19294AF532
Alexa Fluor 594	NB120-19294AF594
Alexa Fluor 647	NB120-19294AF647
Alexa Fluor 700	NB120-19294AF700
Alexa Fluor 750	NB120-19294AF750
Allophycocyanin	NB120-19294APC
Biotin	NB120-19294B
DyLight 350	NB120-19294UV
DyLight 405	NB120-19294V
DyLight 488	NB120-19294G
DyLight 550	NB120-19294R
DyLight 594	NB120-19294DL594
DyLight 650	NB120-19294C
DyLight 680	NB120-19294FR
DyLight 755	NB120-19294IR
FITC	NB120-19294F
HRP	NB120-19294H
Janelia Fluor 549	NB120-19294JF549
Janelia Fluor 646	NB120-19294JF646
PE	NB120-19294PE
PerCP	NB120-19294PCP
mFluor Violet 450 SE	NB120-19294MFV450
mFluor Violet 500 SE	NB120-19294MFV500
mFluor Violet 610 SE	NB120-19294MFV610

compare

(select up to 3 products from this page to compare)

NBP2-52721

LAMP-1/CD107a Antibody (5E7) - BSA Free

(2 Reviews)

(7 Publications)

0.1 mg

NBP2-52721

Immunocytochemistry/Immunofluorescence: LAMP-1/CD107a Antibody (5E7) [NBP2-52721] - A431 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-LAMP (5E7) at a 1:200 dilution overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Immunocytochemistry/Immunofluorescence: LAMP-1/CD107a Antibody (5E7) [NBP2-52721] - MCF-7 human breast cancer cell line. Secondary antibody goat anti-mouse IgG Fc Dy680 (NBP1-72880). Image from verified customer review.

Reactivity:

Hu

Species Glossary

Reactivity: Hu

Applications:

, ,

Applications: , ,

Host:

Mouse Monoclonal

Host: Mouse Monoclonal

Sizes:

Sample Size Available

Sizes: Sample Size Available

Conjugate:

Unconjugated

Available Conjugates:

Conjugate	Catalog #	Availability	Size	Price
Alexa Fluor 350	NBP2-52721AF350
Alexa Fluor 405	NBP2-52721AF405
Alexa Fluor 488	NBP2-52721AF488
Alexa Fluor 532	NBP2-52721AF532
Alexa Fluor 594	NBP2-52721AF594
Alexa Fluor 647	NBP2-52721AF647
Alexa Fluor 700	NBP2-52721AF700
Alexa Fluor 750	NBP2-52721AF750
Allophycocyanin	NBP2-52721APC
Biotin	NBP2-52721B
DyLight 350	NBP2-52721UV
DyLight 405	NBP2-52721V
DyLight 488	NBP2-52721G
DyLight 550	NBP2-52721R
DyLight 594	NBP2-52721DL594
DyLight 650	NBP2-52721C
DyLight 680	NBP2-52721FR
DyLight 755	NBP2-52721IR
FITC	NBP2-52721F
HRP	NBP2-52721H
Janelia Fluor 549	NBP2-52721JF549
Janelia Fluor 646	NBP2-52721JF646
PE	NBP2-52721PE
PerCP	NBP2-52721PCP
mFluor Violet 450 SE	NBP2-52721MFV450
mFluor Violet 500 SE	NBP2-52721MFV500
mFluor Violet 610 SE	NBP2-52721MFV610

Available Formulations

Formulation	Catalog #	Availability	Price
BSA Free	NBP2-52721SS
Azide and BSA Free	NBP2-80824

compare

(select up to 3 products from this page to compare)

At	=	A. thaliana	SyHa	=	Golden Syrian Hamster
All	=	All Species	Ha	=	Hamster
An	=	Animal	Hu	=	Human
ArHa	=	Armenian Hamster	I	=	Insect
Av	=	Avian	Ll	=	Llama
Bb	=	Baboon	Ma	=	Mammal
Ba	=	Bacteria	Mk	=	Monkey
Bv	=	Bovine	Mu	=	Mouse
Ca	=	Canine	Multi	=	Multi-species
Ce	=	C. Elegans	NA	=	Non-species specific
Ch	=	Chicken	Or	=	Orangutan
ChHa	=	Chinese Hamster	Pl	=	Plant
Cm	=	Cynomolgus Monkey	Pm	=	Primate
Do	=	Donkey	Po	=	Porcine
Dr	=	Drosophilia	Rb	=	Rabbit
Ec	=	E. Coli	Rt	=	Rat
Eq	=	Equine	RM	=	Rhesus Macaque
Fe	=	Feline	Sh	=	Sheep
Ft	=	Ferret	Vb	=	Vertebrate
Fi	=	Fish	Vi	=	Virus
Fu	=	Fungi	Xp	=	Xenopus
Ge	=	Gerbil	Ye	=	Yeast
GP	=	Guinea Pig	Ze	=	Zebrafish
Gt	=	Goat

Category

Protein/Target

Applications

Reactivity

Citation

Antibody Validation

Reviews

Host

Available Conjugates

Format

Marker

Modification

Clonality

Clone

Gene Symbol

Images Type

Isotype

Kit Type

Lysate Type

Preservative

Protein Or Peptide

Research Areas

Has Sample Size

Promotional Item

Species Glossary

SR-BI Antibody - BSA Free

TDP-43/TARDBP Antibody (2E2-D3)

TLR4 Antibody (76B357.1) - BSA Free

SR-BI Antibody - BSA Free

TLR3 Antibody (40C1285.6) - BSA Free

TLR7 Antibody - BSA Free

TLR4 Antibody (HTA125) - BSA Free

SR-BI Antibody

TLR4 Inhibitor Peptide Set

SARS Spike Protein Antibody

LAMP-1/CD107a Antibody

LAMP-1/CD107a Antibody (5E7) - BSA Free